May. 15 at 10:05 AM
$INBX Stifel increases their PT to
$325. It’s still very conservative by its own admission. With 109 approval by year end in Chomdro and likely AA in Ewings the company will be near a cash flow breakeven. I still expect them to sell 109 and spin 106 and other assets into a new spinCo like they did in early 2025 with their last drug. 109 alone can fetch
$200 ish a share plus CVR for further payouts with CRC approvals. 106 is worth a lot more if PFS / OS is strong at ESMO in October
